Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study
Sponsor: Barbara Ann Karmanos Cancer Institute
Terminated
Low accrual and early termination
Other terminated trials from Barbara Ann Karmanos Cancer Institute
- Pancreas Adenocarcinoma · Phase PHASE1 · Jul 2025
- Glioblastoma · Phase PHASE1 · May 2024
- Immunotherapy · Phase PHASE1/PHASE2 · Feb 2023
- Metastatic Castration-resistant Prostate Cancer · Phase PHASE3 · Mar 2022
- Castration Levels of Testosterone · Phase PHASE2 · Mar 2022
See all terminations from Barbara Ann Karmanos Cancer Institute
Other Multiple Myeloma and Plasma Cell Neoplasm trials with similar outcome
Listed as NCT00942422, this PHASE2 trial focuses on Multiple Myeloma and Plasma Cell Neoplasm and Precancerous Condition and remains terminated or withdrawn. Sponsored by Barbara Ann Karmanos Cancer Institute, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .